A Phase I Randomized Study of a Specifically Engineered, pH‐Sensitive PCSK9 Inhibitor RN317 (PF‐05335810) in Hypercholesterolemic Subjects on Statin Therapy

This phase I study assessed the safety, tolerability, pharmacokinetics, and pharmacodynamics of RN317 (PF‐05335810), a specifically engineered, pH‐sensitive, humanized proprotein convertase subtilisin kexin type 9 (PCSK9) monoclonal antibody, in hypercholesterolemic subjects (low‐density lipoprotein...

Descripción completa

Detalles Bibliográficos
Autores principales: Levisetti, M, Joh, T, Wan, H, Liang, H, Forgues, P, Gumbiner, B, Garzone, PD
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5351011/
https://www.ncbi.nlm.nih.gov/pubmed/27860267
http://dx.doi.org/10.1111/cts.12430

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5351011/
https://www.ncbi.nlm.nih.gov/pubmed/27860267
http://dx.doi.org/10.1111/cts.12430

Ejemplares similares